Although low-dose dapagliflozin was less effective in preventing hospitalization for heart failure, SGLT-2 inhibitors had similar cardiovascular outcomes in T2D. Canagliflozin and dapagliflozin ...

The study enrolled 3533 participants with T2D and CKD (defined as eGFR 25 to 75mL/min/1.73m 2 and urinary albumin-to-creatinine ratio [UACR] >100 and <5000mg/g). Study participants were randomly ...

Opens in a new tab or window AURORA, Colo. -- Pregnant patients with type 2 diabetes (T2D) treated with semaglutide (Ozempic) had mixed pregnancy outcomes, an observational study found.

Similarly, DALYs rose from 116.29 to 267.47 per 100,000 during the same period, marking an AAPC of 2.75%. Mortality rates, however, showed only a slight decline. The burden of early-onset T2D ...

Semaglutide is now approved for T2D patients with CKD, reducing cardiovascular and kidney disease risks. The FLOW phase 3b trial showed significant reductions in adverse kidney and cardiovascular ...